Home healthcare services specialist AdaptHealth (NASDAQ: AHCO) was hardly looking special on Tuesday. Following news that its latest set of quarterly results didn't meet analyst expectations, the market took a dim view of the company and collectively traded out of it. This left it with a nearly 10% loss in price on the day, compared to the 1.2% increase of the bellwether S&P 500 index.
Bottom-line change not dramatic enough
AdaptHealth published its third-quarter results early that morning, and probably wishes it had taken a sick day for the remainder. Revenue inched up marginally on a year-over-year basis to just under $806 million, while net income per GAAP standards flipped dramatically -- it landed at nearly $23 million ($0.15 per share), against the more than $454 million loss in the same quarter one year ago.
That bottom-line shift was heavy, yet it wasn't sufficient enough to hit the consensus analyst estimate of $0.19 per share. AdaptHealth missed on revenue, too, as those pundits following its stock were collectively modeling slightly over $809 million.
In what feels like an attempt to spin the anemic top-line growth, the company quoted CEO Suzanne Foster as saying that she remains "optimistic about the road ahead. We have identified growth opportunities, we are assembling a high performing team and investing in areas that allow us to serve even more patients in their homes."
Guidance adjustments
Yet management reduced its full-year guidance for both revenue and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). For the former, it's now guiding for $3.22 billion to $3.26 billion; that's down from the former range of nearly $3.26 billion to almost $3.32 billion. It's also only marginally better than the 2023 tally of $3.22 billion, and below the average $3.28 billion analyst estimate.
Adjusted EBITDA is now anticipated to reach $655 million to $675 million. The preceding forecast was $660 million to $700 million.
On a brighter note, AdaptHealth lifted its guidance for free cash flow to $175 million-$195 million for 2024. That's up from the previous range of $160 million to $180 million.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $22,050!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $41,999!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $407,440!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of November 4, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
